Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
InnoCare Pharma Ltd. ( (HK:9969) ) has shared an update.
InnoCare Pharma’s board has formalized detailed terms of reference for its Compensation Committee, originally established in 2019, to strengthen governance over remuneration. The document defines key roles, including senior management, and clarifies that remuneration covers salaries, bonuses, benefits, pensions, incentive payments and share options.
The terms specify that the committee must comprise at least three directors, with a majority being independent non-executive directors and an independent chair, aligning with Hong Kong Listing Rules and STAR Market requirements. The board retains authority to appoint, remove and replace committee members, underscoring a structured framework for oversight of executive pay and compliance across its dual listings.
The most recent analyst rating on (HK:9969) stock is a Hold with a HK$11.50 price target. To see the full list of analyst forecasts on InnoCare Pharma Ltd. stock, see the HK:9969 Stock Forecast page.
More about InnoCare Pharma Ltd.
InnoCare Pharma Limited is a biopharmaceutical company listed in Hong Kong and on Shanghai’s STAR Market, focusing on innovative therapies. The company operates through a group structure that includes various subsidiaries and associated companies, and is governed by a board of directors and senior management subject to Hong Kong and PRC market regulations.
Average Trading Volume: 6,876,447
Technical Sentiment Signal: Sell
Current Market Cap: HK$17.58B
Learn more about 9969 stock on TipRanks’ Stock Analysis page.